Galena Biopharma Inc (NASDAQ:GALE) saw its shares rising nearly 10% in pre-market trading after announcing that two clinical trials evaluating NeuVax™ (nelipepimut-S) in combination …
Galena Biopharma Inc (NASDAQ:GALE) reported its financial results for the quarter ended June 30, 2017. “Last week we made a transformative announcement to merge …
Yesterday, Galena Biopharma Inc (NASDAQ:GALE) and SELLAS Life Sciences announced they have entered into an all stock definitive merger agreement under which SELLAS …
Galena Biopharma, Inc. (NASDAQ:GALE) and SELLAS Life Sciences Group announced they have entered into an all stock definitive merger agreement under which SELLAS will …
Galena Biopharma, Inc. (NASDAQ:GALE) announced an update on the status of the Company and its most advanced clinical development program.
Galena Biopharma Inc (NASDAQ:GALE) announced a poster was presented on the Company’s NeuVax™ (nelipepimut-S) investigator-sponsored Phase 2 clinical trial (IST) in high-risk, HER2 …
Galena Biopharma Inc (NASDAQ:GALE) investors have a smile on their faces Friday morning, after the drug maker announced positive data from the Company’s GALE-301 (E39) investigator-sponsored …
Galena Biopharma Inc (NASDAQ:GALE) reported its financial results for the quarter and year ended December 31, 2016. “I am honored to be selected …
Galena Biopharma Inc (NASDAQ:GALE) announced it has engaged Canaccord Genuity, Inc. as its financial advisor to assist in the previously announced strategic alternative …
Galena Biopharma Inc (NASDAQ:GALE) announced that the Company’s Board of Directors appointed Stephen F. Ghiglieri as Interim Chief Executive Officer, effective today.
